Timothy P. Flanigan Professor of Medicine, Professor of Health Services, Policy and Practice

Dr. Flanigan is a member of the Division of Infectious Diseases at Rhode Island and The Miriam Hospitals and Brown Medical School.
He came to Brown Medical School in 1991 to help establish a network of primary care for HIV infected individuals with a particular focus on women, substance abusers and individuals leaving prison.
Dr. Flanigan developed the HIV Core Program at the State Prison to provide care for HIV infected individuals and link them to community based resources upon release. Over 70% of individuals in Rhode Island who are HIV infected link with primary medical care at The Immunology Center.
Dr. Flanigan has been the PI on two special projects of national significance funded by HRSA to develop combined therapy for opiate addiction and HIV, as well as a model program of linkage to care for HIV positive person's leaving jail. He is also associate director of The Miriam/Brown Fogarty Program which trains and mentors overseas investigators in HIV/AIDS.
He was the recipient of a community health leadership award from The Robert Wood Johnson Foundation for the development of outstanding primary care for underserved HIV infected individuals. In 2005, he received an honorary doctorate from Salve Regina University for his support of educational opportunities for children of incarcerated parents.

Brown Affiliations

Research Areas

scholarly work

Sosman JM, MacGowan R, Margolis A, Gaydos CA, Eldridge G, Moss S, Flanigan T, Iqbal K, Belcher L, for the Project START Biologics Study Group. Sexually transmitted infections and hepatitis in men with a history of incarceration. Sexually Transmitted Diseases. 2011 Jul; 38(7):634-9. PMID: 21844713.

Nunn A, Zaller N, Cornwall A, Dickman S, Flanigan T, Mayer K, Beckwith C, Kwakwa H. Low perceived risk and high HIV prevalence among a predominantly African American population participating in Philadelphia's rapid HIV testing program. AIDS Patient Care and STDs, 25(4):229-235, 2011. PMC3068868

Nunn A, Eng W, Cornwall A, Beckwith C, Dickman S, Flanigan T, Kwakwa H. African American Patient Experiences with a Rapid HIV Testing Program in an Urban Public Clinic. J Nat'l Med Assoc. Dec, 2011.

Tate DF, Delong A, McCaffrey DE, Kertesz K, Paul RH, Conley J, Russell T, Coop K, Gillani F, Flanigan T, Tashima K, Hogan JW. Recent Clinical History and Cognitive Dysfunction for Attention and Executive Function among Human Immunodeficiency Virus-Infected Patients. Arch Clin Neuropsychol. 2011 Aug 25. PMID: 21873325

Venkatesh KK, Flanigan TP, Mayer KH. Is expanded HIV treatment preventing new infections?: Impact of antiretroviral therapy on sexual risk behaviors in the developing world. AIDS. 2011 Aug 5. PMID:21811137

Flanigan TP, Beckwith CG. The Intertwined Epidemics of HIV Infection, Incarceration, and Substance Abuse: A Call to Action. J Infect Dis. 2011 May;203(9):1201-3.PMID: 21459812

research overview

Timothy P. Flanigan has spearheaded both clinical care and clinical research programs for improved HIV treatment among marginalized communities. He has been funded through the CDC, NIH, Substance Abuse and Mental Health Services Administration (SAMSA) and Ryan White to provide improved HIV treatment and prevention among individuals in jail and prison and among active substance abusers. He is also currently engaged in HIV treatment programs in Ghana and Ukraine.

research statement

Timothy P. Flanigan's initial research focused on parasitic infections including Schistosoma mansoni and Cryptosporidium parvum. As effective therapy for HIV became available, Cryptosporidiosis which is a leading cause of diarrheal illness in persons with AIDS has disappeared. Dr. Flanigan subsequently shifted his research focus to HIV care in underserved communities, particularly substance abusers, women, inner-city communities and incarcerated men and women. His early work demonstrated the feasibility of linking individuals with HIV in prison and jail to care in the community after release. The success of this program led to the implementation nationwide of programs of integrated case management that linked HIV-infected persons with medical care upon release. Importantly, among women with HIV, recidivism rates were reduced with this intervention.

Timothy P. Flanigan has since focused on the importance of routine testing for HIV in underserved communities. Approximately ¼ of the HIV infected individuals in this country are unaware of their condition and are not receiving medical care. Programs are underway to evaluate routine HIV testing (and in certain cases rapid testing) in jails, universities, TB clinics, and the primary care setting.

Timothy P. Flanigan has spearheaded a program of intense observed therapy for HIV treatment for individuals who are marginalized and would otherwise not receive the benefit of our new combination HIV treatments. A pilot program for active substance abusers to provide community based treatment strategies is ongoing and has been cited nationally. This work has been presented at the Infectious Disease Society of America, the Conference on New Advances in HIV Therapies sponsored by the American Federation for AIDS Research, and the National Retroviral Conference, and received funding through an RO1 from the National Institutes of Health. Programs to extend these community based therapies for pregnant women and persons leaving prison have begun.

funded research

Title: University of Ghana-Brown University Academic Partnership to Address HIV/AIDS
Funding Agency: Higher Education for Development
Funding Period: Two Years
Two Year Total: $1,100,000
Funding Status: Project funded -

Center for Metabolic Research on HIV and Drug Use
Principal Investigator: Sherwood Gorbach, MD
Agency: NIH/NIDA P30DA013868
Years: 9/1/00-7/31/13
$40, 043, .9 Calendar Months
The goal of the Center is to continue to work to raise awareness of the importance of nutritional and metabolic disorders on outcomes in the drug using population and to encourage investigators to include studies of nutritional and metabolic status n their research in drug using populations.

HIV and Other Infectious Consequences of Substance Abuse
Principal Investigator: Timothy P. Flanigan, MD
Agency: NIH/NIDA 2T32DA13911
Years: 7/1/01-6/30/2012
$386,345/year, .6 Calendar Months
The goal of this training program is to prepare postdoctoral fellows (physicians and behavioral scientists) for research careers in the cross-disciplinary field of HIV and other infections associated with substance abuse

Optimizing HIV Care in Less Developed Countries
Principal Investigator: Kenneth Freedberg, MD
Agency: NIH/NIAID, 2R01A1058736
Years: 9/1/03-6/30/13
$31,269, .6 Calendar Months
This new model will reflect the most current understanding of HIV and AIDS epidemiology, treatment efficacy, impact on TB transmission and cost-effectiveness of care.